RecruitingPhase 2NCT07494565

Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL

A Multicenter, Prospective, Randomized, Open-Label, Phase II Study of Celecoxib Combined With R-CHOP Versus R-CHOP in Patients With Newly Diagnosed Advanced CD5-Positive Diffuse Large B-Cell Lymphoma (CD5+ DLBCL)

Sponsor

Sun Yat-sen University

Enrollment

60 participants

Start Date

Mar 6, 2026

Study Type

INTERVENTIONAL

Conditions

Diffuse Large B-Cell Lymphoma (DLBCL)CD5 Positive

Summary

To evaluate the efficacy of celecoxib combined with R-CHOP versus R-CHOP in the treatment of newly diagnosed advanced CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL).The primary endpoint is Complete Response Rate (CRR)

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Celecoxib Combined with R-CHOP and a drug called R-CHOP for people with cd5 positive and diffuse large b-cell lymphoma (dlbcl). The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCelecoxib Combined with R-CHOP

Drug Dose Administration Time Rituximab (Innovent) 375 mg/m², iv Day 1 Cyclophosphamide 750 mg/m², iv Day 1 Doxorubicin 50 mg/m², iv Day 1 Vincristine 1.4 mg/m² (max. 2 mg), iv Day 1 Prednisone 60 mg/m², po Days 1-5 Celecoxib 200 mg, po, BID Days -3 to +2

DRUGR-CHOP